Suwon-si, South Korea · Founded 2020 · Publicly Held
IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. IMBiologics (KRX: 493280) is based in Suwon-si, South Korea and was founded in 2020. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). It has raised $99.1 million.
Last price · $/share
—
Implied valuation
$261.7M
Total raised
$99.1M
Last round
—
Cap table — not yet on record
IMBiologics (KRX: 493280)'s share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of IMBiologics (KRX: 493280) with a free account
·The complete investor list: 22 names
·Watch IMBiologics (KRX: 493280): the Monday email on marks, rounds and moves
